drugset / Trial / NCT00487825

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

NCT00487825

Phase 2 Completed 78 enrolled Novartis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)

Timeline

Start
2007-03
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 600 mg Intravenous
Background Methotrexate Small molecule 7.5 mg Oral
Background Methotrexate Small molecule 15 mg Oral

Indications